@entity320 presents a therapeutic challenge. @entity1 at high risk for recurrence (stage III) are eligible for adjuvant treatment with @entity3027 or may enrol in a clinical trial. Both options offer no meaningful survival advantage. @entity1 with @entity3 (stage IV) have a 5-year survival of < 10% and have no effective treatment options. Despite aggressive investigations into vaccine therapy, no vaccine has yet received FDA approval. Biological therapies with @entity3027 and @entity1199 have demonstrated a real but minimal effect. Chemotherapeutic options are even more dismal. Single-agent chemotherapy yields a 15-20% response rate of short lived duration. Combination chemotherapy alone or with immunological adjuvants yields response rates of 35-45% but with significant @entity137 and no significant improvement in survival. Novel treatment agents that target metabolic pathways, angiogenesis inhibitors, antisense therapies, gene therapies and innovative vaccines may offer hope for an otherwise grave disease.

Novel therapeutic agents under investigation for XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity3027 :: ('3439', 'Gene') :: ['IFN-alpha'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease'] @entity1199 :: ('3558', 'Gene') :: ['IL-2'] @entity320 :: ('MESH:D008545', 'Disease') :: ['Malignant melanoma']
@entity320 :: (MESH:D008545,Disease) :: ['malignant melanoma']
